Fulcrum Therapeutics, Inc.
FULC
$6.92
-$0.51-6.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -360.49% | 10.08% | |||
| Gross Profit | 360.49% | -10.08% | |||
| SG&A Expenses | -3.77% | 10.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.82% | 10.31% | |||
| Operating Income | -3.82% | -10.31% | |||
| Income Before Tax | -3.77% | -13.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.77% | -13.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.77% | -13.29% | |||
| EBIT | -3.82% | -10.31% | |||
| EBITDA | -3.88% | -10.48% | |||
| EPS Basic | 1.25% | -13.20% | |||
| Normalized Basic EPS | 1.23% | -13.19% | |||
| EPS Diluted | 0.58% | -11.79% | |||
| Normalized Diluted EPS | 1.23% | -13.19% | |||
| Average Basic Shares Outstanding | 5.09% | 0.08% | |||
| Average Diluted Shares Outstanding | 5.09% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||